1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Hikma Will Push Harder To Make M&A Happen

Executive Chairman And CEO Said Darwazah Talks Strategy Following Fall In Guidance

 
• By Dave Wallace

Following a challenging first half for Hikma, executive chairman and CEO Said Darwazah talks to Generics Bulletin about how the firm is planning to be more active in making deals happen, as well as how it plans to address pressures on its Generics division that led to two consecutive downgrades in guidance this year.

Deal abstract businessmen red white
Sometimes you have to push to make deals happen, Darawazah says • Source: Shutterstock

Speaking to Hikma executive chairman and CEO Said Darwazah immediately after the company reported flat half-year sales and revised down its generics forecasts for the second time this year, the chief executive made clear that the company has a strategy in place to return the company to growth across all three of its business units, including Generics.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.